Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning Improves Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).

被引：0
|
作者：
Khouri, Issa F. [1 ]
Saliba, Rima M. [1 ]
Ledesma, Celina [1 ]
Jabbour, Elias J. [2 ]
Turturro, Francesco [3 ]
Alatrash, Gheath [4 ]
Ahmed, Sairah [1 ]
Oran, Betul [1 ]
Patel, Krina K. [1 ]
Olson, Amanda [4 ]
Marin, David [1 ]
Popat, Uday R. [1 ]
Suki, Tina S. [1 ]
Jorgensen, Jeffrey L. [5 ]
Medeiros, L. Jeffrey [5 ]
Gulbis, Alison M. [6 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
[6] Univ Texas MD Anderson Canc Ctr, Div Pharm, Houston, TX 77030 USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Bfr (bendamustine, fludarabine, rituximab) Vs. FCR Nonmyeloablative Allogeneic Conditioning In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Outcome Results Including Minimal Residual Disease Analysis
    Khouri, Issa F.
    Saliba, Rima M.
    Challagundla, Pramoda
    Ledesma, Celina
    Korbling, Martin
    Gulbis, Alison M.
    Guillermo-Pacheco, Maria
    Ahmed, Sairah
    Anderlini, Paolo
    Bashir, Qaiser
    Oran, Betul
    Ciurea, Stefan O.
    Hosing, Chitra M.
    Kebriaei, Partow
    Popat, Uday R.
    Jabbour, Elias
    Champlin, Richard E.
    Jorgensen, Jeffrey L.
    BLOOD, 2013, 122 (21)
  • [2] BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD
    Khouri, Issa F.
    Wei, Wei
    Korbling, Martin
    Turturro, Francesco
    Ahmed, Sairah
    Alousi, Amin
    Anderlini, Paolo
    Ciurea, Stefan
    Jabbour, Elias
    Oran, Betul
    Popat, Uday R.
    Rondon, Gabriela
    Bassett, Roland L., Jr.
    Gulbis, Alison
    BLOOD, 2014, 124 (14) : 2306 - 2312
  • [3] Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning for Lymphoid Malignancies: 8-Year Results
    Khouri, Issa F.
    Jabbour, Elias J.
    Ledesma, Celina
    Korbling, Martin
    Alousi, Amin M.
    Anderlini, Paolo
    Oran, Betul
    Ciurea, Stefan O.
    Fayad, Luis E.
    Bassett, Roland L., Jr.
    Gulbis, Alison M.
    BLOOD, 2017, 130
  • [4] Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning: A Novel Regimen Inducing Immunosuppression Without Myelosuppression
    Khouri, Issa F.
    Wei, Wei
    Valverde, Rosamar
    Korbling, Martin
    Turturro, Francesco
    Gulbis, Alison M.
    Guillermo-Pacheco, Maria
    Ahmed, Sairah
    Alousi, Amin
    Oran, Betul
    Anderlini, Paolo
    Ciurea, Stefan O.
    Hosing, Chitra M.
    Popat, Uday R.
    Jabbour, Elias
    Champlin, Richard E.
    Bassett, Roland
    BLOOD, 2013, 122 (21)
  • [5] Efficacy Of Bendamustine and Rituximab In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
    Kataeva, Elena
    Golenkov, Anatoly
    Triphonova, Elena
    Dudina, Galina
    Mitina, Tatyana
    Lutskaya, Tatyana
    Vysotskaya, Ludmila
    Chernykh, Yulliya
    Zakharov, Sergey
    BLOOD, 2013, 122 (21)
  • [6] Improved survival in patients with relapsed - Refractory chronic lymphocytic leukemia (CLL) treated with fludarabine, cyclophosphamide, and rituximab (FCR) combination.
    Wierda, W
    O'Brien, S
    Faderl, S
    Ferrajoli, A
    Lerner, S
    Wang, XM
    Thomas, D
    Garcia-Manero, G
    Cortes, J
    Kantarjian, H
    Keating, M
    BLOOD, 2003, 102 (11) : 110A - 110A
  • [7] Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
    Wierda, W
    O'Brien, S
    Wen, S
    Faderl, S
    Garcia-Manero, G
    Thomas, D
    Do, KA
    Cortes, J
    Koller, C
    Beran, M
    Ferrajoli, A
    Giles, F
    Lerner, S
    Albitar, M
    Kantarjian, H
    Keating, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) : 4070 - 4078
  • [8] EFFICACY OF THE COMBINATION OF BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
    Zagoskina, T.
    Zotina, E.
    Ovsepyan, V.
    Shardakov, V.
    HAEMATOLOGICA, 2014, 99 : 591 - 591
  • [9] Lumiliximab with fludarabine, cyclophosphamide, and rituximab (FCR) for patients with relapsed chronic lymphocytic leukemia (CLL).
    O'Brien, S.
    Byrd, J. C.
    Kipps, T. J.
    Forero-Torres, A.
    Flinn, I. W.
    Wynne, D. I.
    Molina, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 360S - 360S
  • [10] Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Kipps, Thomas J.
    Wierda, William G.
    Jones, Jeffrey A.
    Swinnen, Lode J.
    Yang, Jianning
    Cui, Yue
    Busman, Todd
    Krivoshik, Andrew
    Enschede, Sari
    Humerickhouse, Rod
    BLOOD, 2010, 116 (21) : 1019 - 1019
12345